{"id":37006,"date":"2026-06-10T18:32:28","date_gmt":"2026-06-10T13:02:28","guid":{"rendered":"https:\/\/atsixty.com\/?p=37006"},"modified":"2026-06-10T19:01:20","modified_gmt":"2026-06-10T13:31:20","slug":"cardiovascular-pharmacology","status":"publish","type":"post","link":"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/","title":{"rendered":"Cardiovascular Pharmacology"},"content":{"rendered":"\n<!-- BOLUS \u00b7 Cardiovascular Pharmacology \u00b7 Mr. Sharma -->\n<div id=\"bolusc01\" style=\"font-family:'Segoe UI',Arial,sans-serif;max-width:620px;margin:0 auto;padding:8px 4px;\">\n\n<style>\n#bolusc01 *{box-sizing:border-box;}\n\n#bolusc01 .bl-header{\n  background:linear-gradient(135deg,#1565C0 0%,#1976D2 60%,#1E88E5 100%);\n  border-radius:10px;\n  padding:18px 20px 15px;\n  margin-bottom:16px;\n  text-align:center;\n  width:100%;\n  display:block;\n  box-shadow:0 2px 8px rgba(21,101,192,0.18);\n}\n#bolusc01 .bl-header .bl-topic{\n  font-size:0.7rem;\n  color:rgba(255,255,255,0.75);\n  letter-spacing:0.1em;\n  text-transform:uppercase;\n  margin-bottom:4px;\n}\n#bolusc01 .bl-header h2{\n  margin:0 0 5px;\n  font-size:1.4rem;\n  font-weight:800;\n  letter-spacing:0.12em;\n  text-transform:uppercase;\n  color:#fff;\n}\n#bolusc01 .bl-header .bl-tagline{\n  font-size:0.75rem;\n  color:rgba(255,255,255,0.8);\n  font-style:italic;\n  letter-spacing:0.02em;\n}\n\n#bolusc01 .bl-patient{\n  font-size:0.79rem;\n  color:#1565C0;\n  font-weight:600;\n  margin:0 0 12px;\n  letter-spacing:0.02em;\n}\n\n#bolusc01 .bl-progress{\n  display:flex;\n  gap:7px;\n  margin-bottom:20px;\n  flex-wrap:wrap;\n  justify-content:center;\n}\n#bolusc01 .bl-ball{\n  width:15px;height:15px;\n  border-radius:50%;\n  background:#dde3ed;\n  border:2px solid #b0bcd4;\n  transition:background 0.25s,border 0.25s;\n}\n#bolusc01 .bl-ball.correct{background:#2E7D52;border-color:#2E7D52;}\n#bolusc01 .bl-ball.wrong{background:#B94040;border-color:#B94040;}\n#bolusc01 .bl-ball.active{border-color:#1565C0;background:#cfdcf5;}\n\n#bolusc01 .bl-card{display:none;}\n#bolusc01 .bl-card.active{display:block;}\n\n#bolusc01 .bl-qnum{\n  font-size:0.72rem;color:#aaa;\n  font-weight:700;letter-spacing:0.07em;\n  text-transform:uppercase;margin-bottom:5px;\n}\n#bolusc01 .bl-context{\n  font-size:0.79rem;color:#5a6a85;\n  font-style:italic;margin-bottom:10px;\n  line-height:1.5;\n  border-left:3px solid #bbcfe8;\n  padding-left:10px;\n}\n#bolusc01 .bl-qtext{\n  font-size:0.97rem;font-weight:600;\n  color:#1a1a2e;line-height:1.55;\n  margin-bottom:13px;\n}\n#bolusc01 .bl-options{list-style:none;padding:0;margin:0;}\n#bolusc01 .bl-options li{\n  border:1.5px solid #c8d3e8;\n  border-radius:7px;\n  padding:10px 14px;\n  margin-bottom:8px;\n  cursor:pointer;\n  font-size:0.91rem;\n  color:#1a1a2e;\n  transition:background 0.15s,border 0.15s;\n  line-height:1.4;\n}\n#bolusc01 .bl-options li:hover:not(.disabled){\n  background:#eef3fc;border-color:#1565C0;\n}\n#bolusc01 .bl-options li.correct{\n  background:#e6f4ec;border-color:#2E7D52;\n  color:#1a3d29;font-weight:600;\n}\n#bolusc01 .bl-options li.wrong{\n  background:#fdecea;border-color:#B94040;color:#5c1a1a;\n}\n#bolusc01 .bl-options li.reveal{\n  background:#e6f4ec;border-color:#2E7D52;\n}\n#bolusc01 .bl-options li.disabled{cursor:default;}\n\n#bolusc01 .bl-explanation{\n  background:#f0f5fc;\n  border-left:3px solid #1565C0;\n  border-radius:0 6px 6px 0;\n  padding:11px 14px;\n  margin-top:12px;\n  font-size:0.85rem;\n  color:#2a2a3e;\n  line-height:1.62;\n  display:none;\n}\n#bolusc01 .bl-explanation.show{display:block;}\n#bolusc01 .bl-explanation p{margin:0 0 7px;}\n#bolusc01 .bl-explanation p:last-child{margin:0;}\n\n#bolusc01 .bl-next{\n  margin-top:14px;\n  background:#1565C0;color:#fff;\n  border:none;border-radius:7px;\n  padding:9px 26px;\n  font-size:0.9rem;font-weight:600;\n  cursor:pointer;display:none;\n  letter-spacing:0.02em;\n}\n#bolusc01 .bl-next.show{display:inline-block;}\n#bolusc01 .bl-next:hover{background:#0d47a1;}\n\n#bolusc01 .bl-result{display:none;text-align:center;padding:22px 8px;}\n#bolusc01 .bl-result.show{display:block;}\n#bolusc01 .bl-result h3{font-size:1.1rem;color:#1565C0;margin-bottom:4px;}\n#bolusc01 .bl-result .bl-end-tag{\n  font-size:0.84rem;color:#555;\n  font-style:italic;margin-bottom:18px;\n  line-height:1.5;\n}\n#bolusc01 .bl-score-big{\n  font-size:2.8rem;font-weight:700;\n  color:#1a1a2e;line-height:1;\n}\n#bolusc01 .bl-score-sub{font-size:0.8rem;color:#aaa;margin-top:3px;}\n#bolusc01 .bl-score-detail{\n  margin-top:14px;font-size:0.86rem;\n  color:#555;line-height:1.9;\n}\n#bolusc01 .bl-restart{\n  margin-top:18px;\n  background:#1565C0;color:#fff;\n  border:none;border-radius:7px;\n  padding:10px 28px;\n  font-size:0.9rem;font-weight:600;cursor:pointer;\n}\n#bolusc01 .bl-restart:hover{background:#0d47a1;}\n<\/style>\n\n<div class=\"bl-header\">\n  <div class=\"bl-topic\">Cardiovascular Pharmacology<\/div>\n  <h2>Bolus<\/h2>\n  <div class=\"bl-tagline\">One patient. One story. Ten drug decisions.<\/div>\n<\/div>\n\n<div class=\"bl-patient\" id=\"bolusc01-patient\">\u21b3 Mr. Sharma, 52. His story begins.<\/div>\n<div class=\"bl-progress\" id=\"bolusc01-progress\"><\/div>\n<div id=\"bolusc01-cards\"><\/div>\n\n<div class=\"bl-result\" id=\"bolusc01-result\">\n  <h3>Mr. Sharma made it.<\/h3>\n  <div class=\"bl-end-tag\" id=\"bolusc01-endtag\"><\/div>\n  <div class=\"bl-score-big\" id=\"bolusc01-score-big\"><\/div>\n  <div class=\"bl-score-sub\" id=\"bolusc01-score-sub\"><\/div>\n  <div class=\"bl-score-detail\" id=\"bolusc01-score-detail\"><\/div>\n  <button class=\"bl-restart\" id=\"bolusc01-restart\">\u21bb Visit Again<\/button>\n<\/div>\n\n<script>\n(function(){\n  var NS = 'bolusc01';\n\n  var data = [\n    {\n      context: \"Mr. Sharma, 52, visits with BP 158\/96 mmHg on two separate readings. No diabetes, no kidney disease, no prior cardiac history. You decide to start monotherapy.\",\n      q: \"Which drug is the most commonly preferred first-line agent for uncomplicated hypertension in Indian clinical practice?\",\n      opts: [\"Amlodipine 5 mg\",\"Telmisartan 40 mg\",\"Hydrochlorothiazide 12.5 mg\",\"Atenolol 50 mg\"],\n      ans: \"Telmisartan 40 mg\",\n      exp: \"ARBs \u2014 particularly Telmisartan and Losartan \u2014 are the most frequently chosen first-line agents for uncomplicated hypertension in Indian practice, favoured for once-daily dosing, excellent tolerability, and end-organ protection. Telmisartan has the longest half-life among ARBs (24 hours), providing consistent 24-hour BP control. All four major classes remain guideline-accepted, but ARBs have overtaken ACE inhibitors as the default choice due to the complete absence of cough.\"\n    },\n    {\n      context: \"Mr. Sharma is started on Telmisartan 40 mg. He returns after 6 weeks. BP is 146\/92 \u2014 still above target. No complaints. You consider adding a second agent.\",\n      q: \"When combining a second antihypertensive with an ARB, which class is the most rational and synergistic addition?\",\n      opts: [\"Another ARB at higher dose\",\"A calcium channel blocker such as Amlodipine\",\"A beta-blocker such as Atenolol\",\"An ACE inhibitor such as Ramipril\"],\n      ans: \"A calcium channel blocker such as Amlodipine\",\n      exp: \"ARB + CCB (Telmisartan + Amlodipine) is the most evidence-backed dual combination in hypertension, acting on complementary pathways \u2014 RAAS blockade plus direct arterial vasodilation \u2014 with additive BP reduction and no pharmacological antagonism. Combining two RAAS agents (ARB + ACE inhibitor) is specifically contraindicated due to risk of hyperkalaemia and acute kidney injury.\"\n    },\n    {\n      context: \"Mr. Sharma is on Telmisartan 40 mg and Amlodipine 5 mg. BP is 128\/80. Three months later he reports exertional chest tightness and is diagnosed with stable angina.\",\n      q: \"A beta-blocker is added for angina. Which property makes a beta-blocker preferable over non-selective agents in this setting?\",\n      opts: [\"Longer half-life\",\"Cardioselectivity (\u03b21-selectivity)\",\"Lipid solubility\",\"Intrinsic sympathomimetic activity\"],\n      ans: \"Cardioselectivity (\u03b21-selectivity)\",\n      exp: \"\u03b21-selective blockers \u2014 metoprolol, bisoprolol, atenolol \u2014 act primarily on cardiac \u03b21 receptors, reducing heart rate, contractility, and myocardial oxygen demand. Non-selective beta-blockers also block \u03b22 receptors, risking bronchospasm in susceptible patients. Cardioselectivity is the key property for angina management, though it is relative, not absolute, and diminishes at higher doses.\"\n    },\n    {\n      context: \"Mr. Sharma is on Telmisartan, Amlodipine, Bisoprolol, and sublingual GTN for acute attacks. He asks why he cannot use the GTN spray continuously.\",\n      q: \"Why is a nitrate-free interval required with continuous nitrate therapy?\",\n      opts: [\"Nitrates cause rebound hypertension if used continuously\",\"Continuous use causes tachyphylaxis due to depletion of sulfhydryl groups\",\"Nitrates accumulate and cause methemoglobinemia\",\"Continuous use leads to beta-receptor downregulation\"],\n      ans: \"Continuous use causes tachyphylaxis due to depletion of sulfhydryl groups\",\n      exp: \"Nitrate tolerance develops with continuous exposure due to depletion of intracellular sulfhydryl (-SH) groups required for nitric oxide generation, compounded by counter-regulatory neurohormonal activation. A nitrate-free interval of 8\u201310 hours \u2014 typically overnight \u2014 restores sensitivity. Long-acting nitrate formulations are therefore prescribed with asymmetric dosing: morning and afternoon, not bedtime.\"\n    },\n    {\n      context: \"Two years later Mr. Sharma presents with breathlessness on mild exertion, bilateral ankle oedema, and orthopnoea. Echo shows EF of 36% \u2014 heart failure with reduced ejection fraction (HFrEF).\",\n      q: \"Which aldosterone antagonist has demonstrated mortality benefit in HFrEF and should be added to his regimen?\",\n      opts: [\"Furosemide\",\"Spironolactone\",\"Hydrochlorothiazide\",\"Metolazone\"],\n      ans: \"Spironolactone\",\n      exp: \"Spironolactone, proven in the landmark RALES trial, significantly reduces mortality and hospitalisation in HFrEF \u2014 a benefit arising from blockade of aldosterone-mediated myocardial fibrosis and adverse cardiac remodelling, not merely its diuretic effect. It is the third pillar of HFrEF pharmacotherapy alongside RAAS blockade and beta-blocker. Eplerenone is the alternative with fewer antiandrogenic side effects. Monitor potassium carefully \u2014 hyperkalaemia is the principal risk.\"\n    },\n    {\n      context: \"Mr. Sharma's cardiologist upgrades therapy. Telmisartan is replaced by Sacubitril-Valsartan, combining a neprilysin inhibitor with an ARB.\",\n      q: \"What mandatory washout period is required before starting Sacubitril-Valsartan after an ACE inhibitor, and what does it prevent?\",\n      opts: [\"12 hours \u2014 prevents hypotension\",\"24 hours \u2014 prevents rebound hypertension\",\"36 hours \u2014 prevents angioedema\",\"48 hours \u2014 prevents hyperkalaemia\"],\n      ans: \"36 hours \u2014 prevents angioedema\",\n      exp: \"Sacubitril inhibits neprilysin, which normally degrades bradykinin. Combined with an ACE inhibitor (which also elevates bradykinin), levels rise to dangerous levels causing potentially fatal angioedema. A mandatory 36-hour washout after the last ACE inhibitor dose is required before starting Sacubitril-Valsartan. Since Mr. Sharma was on an ARB, direct switch is permissible \u2014 but the rule is critical for exam and practice.\"\n    },\n    {\n      context: \"Six months after the upgrade, Mr. Sharma develops palpitations. ECG shows atrial fibrillation with a ventricular rate of 134\/min.\",\n      q: \"For rate control in AF with coexistent HFrEF, which drug class is preferred and which is contraindicated?\",\n      opts: [\"Digoxin preferred; beta-blockers contraindicated\",\"Beta-blockers preferred; non-dihydropyridine CCBs contraindicated\",\"Verapamil preferred; digoxin contraindicated\",\"Amiodarone preferred; beta-blockers contraindicated\"],\n      ans: \"Beta-blockers preferred; non-dihydropyridine CCBs contraindicated\",\n      exp: \"Beta-blockers (metoprolol, bisoprolol, carvedilol) slow AV nodal conduction and are preferred for rate control in AF with HFrEF \u2014 with independent mortality benefit in heart failure. Non-dihydropyridine CCBs (verapamil, diltiazem) are contraindicated in HFrEF due to significant negative inotropy that worsens cardiac function. Digoxin is second-line, suitable mainly in sedentary patients where modest rate control targets suffice.\"\n    },\n    {\n      context: \"Mr. Sharma's AF is confirmed persistent. CHA\u2082DS\u2082-VASc score is 4, indicating high stroke risk. Anticoagulation is initiated.\",\n      q: \"Which anticoagulant class has replaced warfarin as first-line in non-valvular AF?\",\n      opts: [\"Low molecular weight heparins\",\"Vitamin K antagonists (warfarin)\",\"Direct oral anticoagulants (DOACs)\",\"Dual antiplatelet therapy\"],\n      ans: \"Direct oral anticoagulants (DOACs)\",\n      exp: \"DOACs \u2014 dabigatran (direct thrombin inhibitor) and rivaroxaban, apixaban, edoxaban (factor Xa inhibitors) \u2014 are now first-line for stroke prevention in non-valvular AF. Predictable pharmacokinetics, no INR monitoring, fewer interactions, and significantly lower intracranial haemorrhage rates have replaced warfarin as default. Warfarin remains preferred in AF with mechanical heart valves or significant rheumatic mitral stenosis, where DOACs are not validated.\"\n    },\n    {\n      context: \"Routine bloods show LDL 4.3 mmol\/L. With established cardiovascular disease, aggressive lipid lowering is now mandatory.\",\n      q: \"Which statin intensity is recommended for secondary prevention in established CVD?\",\n      opts: [\"Low-intensity; 20\u201330% LDL reduction\",\"Moderate-intensity; 30\u201340% LDL reduction\",\"High-intensity; \u226550% LDL reduction\",\"Any statin; LDL target is not evidence-based\"],\n      ans: \"High-intensity; \u226550% LDL reduction\",\n      exp: \"Secondary prevention mandates high-intensity statin therapy \u2014 atorvastatin 40\u201380 mg or rosuvastatin 20\u201340 mg \u2014 targeting LDL <1.4 mmol\/L or >50% reduction from baseline. These inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. If target is not achieved, ezetimibe is added; PCSK9 inhibitors are reserved for refractory cases or familial hypercholesterolaemia.\"\n    },\n    {\n      context: \"Mr. Sharma, now 61, is admitted with crushing chest pain. ECG shows ST elevation in leads II, III, aVF. Primary PCI is performed. Post-procedure medications are being finalised.\",\n      q: \"Which antiplatelet combination is standard after primary PCI for STEMI, and for how long?\",\n      opts: [\"Aspirin alone for 6 months\",\"Aspirin + Clopidogrel for 6 months\",\"Aspirin + Ticagrelor or Prasugrel for 12 months\",\"Ticagrelor alone for 12 months\"],\n      ans: \"Aspirin + Ticagrelor or Prasugrel for 12 months\",\n      exp: \"DAPT with aspirin and a potent P2Y12 inhibitor \u2014 ticagrelor or prasugrel \u2014 for 12 months is standard post-primary PCI, preventing in-stent thrombosis. Both are preferred over clopidogrel for faster onset and more potent, predictable platelet inhibition in the acute ACS setting. After 12 months, aspirin monotherapy continues indefinitely. Prasugrel is avoided if prior stroke\/TIA, age >75, or weight <60 kg due to excess bleeding risk.\"\n    }\n  ];\n\n  var patientLines = [\n    \"\u21b3 Mr. Sharma, 52. His story begins.\",\n    \"\u21b3 Visit 2. BP still above target.\",\n    \"\u21b3 Visit 3. Chest tightness on exertion.\",\n    \"\u21b3 Visit 4. A patient asks about his spray.\",\n    \"\u21b3 Visit 5. Breathless. Heart is failing.\",\n    \"\u21b3 Visit 6. Therapy upgraded.\",\n    \"\u21b3 Visit 7. Heart loses its rhythm.\",\n    \"\u21b3 Visit 8. Stroke risk \u2014 anticoagulation decision.\",\n    \"\u21b3 Visit 9. Lipids dangerously high.\",\n    \"\u21b3 Visit 10. STEMI. The final call.\"\n  ];\n\n  var current = 0;\n  var correct = 0;\n  var wrong = 0;\n\n  function renderProgress(){\n    var p = document.getElementById(NS+'-progress');\n    p.innerHTML = '';\n    for(var i=0;i<data.length;i++){\n      var b = document.createElement('div');\n      b.className = 'bl-ball'+(i===0?' active':'');\n      b.id = NS+'-ball-'+i;\n      p.appendChild(b);\n    }\n  }\n\n  function renderCards(){\n    var container = document.getElementById(NS+'-cards');\n    container.innerHTML = '';\n    for(var i=0;i<data.length;i++){\n      var d = data[i];\n      var card = document.createElement('div');\n      card.className = 'bl-card'+(i===0?' active':'');\n      card.id = NS+'-card-'+i;\n\n      var qnum = document.createElement('div');\n      qnum.className = 'bl-qnum';\n      qnum.textContent = 'Visit '+(i+1)+' of '+data.length;\n\n      var ctx = document.createElement('div');\n      ctx.className = 'bl-context';\n      ctx.textContent = d.context;\n\n      var qtext = document.createElement('div');\n      qtext.className = 'bl-qtext';\n      qtext.textContent = d.q;\n\n      var ul = document.createElement('ul');\n      ul.className = 'bl-options';\n      ul.id = NS+'-opts-'+i;\n\n      for(var j=0;j<d.opts.length;j++){\n        var li = document.createElement('li');\n        li.textContent = d.opts[j];\n        li.setAttribute('data-opt', d.opts[j]);\n        li.setAttribute('data-idx', i);\n        li.onclick = handleAnswer;\n        ul.appendChild(li);\n      }\n\n      var exp = document.createElement('div');\n      exp.className = 'bl-explanation';\n      exp.id = NS+'-exp-'+i;\n      var paras = d.exp.split('\\n\\n');\n      for(var k=0;k<paras.length;k++){\n        var para = document.createElement('p');\n        para.textContent = paras[k];\n        exp.appendChild(para);\n      }\n\n      var nextBtn = document.createElement('button');\n      nextBtn.className = 'bl-next';\n      nextBtn.id = NS+'-next-'+i;\n      nextBtn.textContent = i < data.length-1 ? 'Next Visit \u2192' : 'See Results';\n      nextBtn.setAttribute('data-idx', i);\n      nextBtn.onclick = handleNext;\n\n      card.appendChild(qnum);\n      card.appendChild(ctx);\n      card.appendChild(qtext);\n      card.appendChild(ul);\n      card.appendChild(exp);\n      card.appendChild(nextBtn);\n      container.appendChild(card);\n    }\n  }\n\n  function handleAnswer(e){\n    var li = e.currentTarget;\n    var idx = parseInt(li.getAttribute('data-idx'));\n    var chosen = li.getAttribute('data-opt');\n    var ans = data[idx].ans;\n\n    var ul = document.getElementById(NS+'-opts-'+idx);\n    var items = ul.getElementsByTagName('li');\n    for(var i=0;i<items.length;i++){\n      items[i].onclick = null;\n      items[i].className = 'disabled';\n      if(items[i].getAttribute('data-opt') === ans){\n        items[i].className += ' correct reveal';\n      }\n    }\n\n    var isCorrect = (chosen === ans);\n    if(isCorrect){ li.className = 'correct disabled'; correct++; }\n    else { li.className = 'wrong disabled'; wrong++; }\n\n    var ball = document.getElementById(NS+'-ball-'+idx);\n    ball.className = 'bl-ball '+(isCorrect?'correct':'wrong');\n\n    document.getElementById(NS+'-exp-'+idx).className = 'bl-explanation show';\n    document.getElementById(NS+'-next-'+idx).className = 'bl-next show';\n  }\n\n  function handleNext(e){\n    var idx = parseInt(e.currentTarget.getAttribute('data-idx'));\n    document.getElementById(NS+'-card-'+idx).className = 'bl-card';\n    if(idx < data.length-1){\n      current = idx+1;\n      document.getElementById(NS+'-card-'+current).className = 'bl-card active';\n      var ball = document.getElementById(NS+'-ball-'+current);\n      if(ball.className === 'bl-ball') ball.className = 'bl-ball active';\n      document.getElementById(NS+'-patient').textContent = patientLines[current];\n    } else {\n      showResult();\n    }\n  }\n\n  function showResult(){\n    document.getElementById(NS+'-cards').innerHTML = '';\n    document.getElementById(NS+'-patient').style.display = 'none';\n\n    var total = data.length;\n    var maxScore = total * 4;\n    var netScore = (correct * 4) - (wrong * 1);\n    var pct = Math.round((netScore \/ maxScore) * 100);\n    if(pct < 0) pct = 0;\n\n    var scoreDisplay = netScore + ' \/ ' + maxScore;\n    var subDisplay = pct + '% \u00b7 ' + correct + ' correct \u00b7 ' + wrong + ' wrong';\n\n    var tag, title;\n    if(pct >= 90){\n      title = 'Mr. Sharma made it. Brilliantly.';\n      tag = '\ud83c\udfc6 Outstanding. Mr. Sharma wants you as his personal cardiologist.';\n    } else if(pct >= 70){\n      title = 'Mr. Sharma made it.';\n      tag = 'Solid round. A dependable hand at the bedside.';\n    } else if(pct >= 50){\n      title = 'Mr. Sharma just about made it.';\n      tag = 'Getting there. The misses are worth a second look.';\n    } else if(pct >= 30){\n      title = 'Mr. Sharma is not well.';\n      tag = 'Rough round. He\\'d like a second opinion. Urgently.';\n    } else {\n      title = 'Mr. Sharma did not make it.';\n      tag = '\u26a0\ufe0f His relatives are on their way to the OPD. Run.';\n    }\n\n    document.getElementById(NS+'-result').querySelector('h3').textContent = title;\n    document.getElementById(NS+'-endtag').textContent = tag;\n    document.getElementById(NS+'-score-big').textContent = scoreDisplay;\n    document.getElementById(NS+'-score-sub').textContent = subDisplay;\n    document.getElementById(NS+'-score-detail').innerHTML = 'Negative marking applied &nbsp;\u00b7&nbsp; Max score +' + maxScore;\n    document.getElementById(NS+'-result').className = 'bl-result show';\n  }\n\n  document.getElementById(NS+'-restart').onclick = function(){\n    current=0; correct=0; wrong=0;\n    document.getElementById(NS+'-patient').style.display='';\n    document.getElementById(NS+'-patient').textContent = patientLines[0];\n    document.getElementById(NS+'-result').className='bl-result';\n    renderProgress();\n    renderCards();\n  };\n\n  renderProgress();\n  renderCards();\n})();\n<\/script>\n<\/div>\n<!-- END BOLUS \u00b7 Cardiovascular Pharmacology \u00b7 Mr. Sharma -->\n\n\n","protected":false},"excerpt":{"rendered":"<p>Cardiovascular Pharmacology Bolus One patient. One story. Ten drug decisions. \u21b3 Mr. Sharma, 52. His story begins. Mr. Sharma made it. \u21bb Visit Again<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[78,66,18,79],"tags":[],"class_list":["post-37006","post","type-post","status-publish","format-standard","hentry","category-bolus","category-cardiology","category-cms","category-pharmacology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cardiovascular Pharmacology - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiovascular Pharmacology - atsixty\" \/>\n<meta property=\"og:description\" content=\"Cardiovascular Pharmacology Bolus One patient. One story. Ten drug decisions. \u21b3 Mr. Sharma, 52. His story begins. Mr. Sharma made it. \u21bb Visit Again\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-10T13:02:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T13:31:20+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/cardiovascular-pharmacology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/cardiovascular-pharmacology\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Cardiovascular Pharmacology\",\"datePublished\":\"2026-06-10T13:02:28+00:00\",\"dateModified\":\"2026-06-10T13:31:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/cardiovascular-pharmacology\\\/\"},\"wordCount\":23,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"articleSection\":[\"Bolus\",\"Cardiology\",\"CMS\",\"Pharmacology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/cardiovascular-pharmacology\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/cardiovascular-pharmacology\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/cardiovascular-pharmacology\\\/\",\"name\":\"Cardiovascular Pharmacology - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-06-10T13:02:28+00:00\",\"dateModified\":\"2026-06-10T13:31:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/cardiovascular-pharmacology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/cardiovascular-pharmacology\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/cardiovascular-pharmacology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardiovascular Pharmacology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardiovascular Pharmacology - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/","og_locale":"en_US","og_type":"article","og_title":"Cardiovascular Pharmacology - atsixty","og_description":"Cardiovascular Pharmacology Bolus One patient. One story. Ten drug decisions. \u21b3 Mr. Sharma, 52. His story begins. Mr. Sharma made it. \u21bb Visit Again","og_url":"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/","og_site_name":"atsixty","article_published_time":"2026-06-10T13:02:28+00:00","article_modified_time":"2026-06-10T13:31:20+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Cardiovascular Pharmacology","datePublished":"2026-06-10T13:02:28+00:00","dateModified":"2026-06-10T13:31:20+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/"},"wordCount":23,"commentCount":0,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"articleSection":["Bolus","Cardiology","CMS","Pharmacology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/","url":"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/","name":"Cardiovascular Pharmacology - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-06-10T13:02:28+00:00","dateModified":"2026-06-10T13:31:20+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/cms\/cardiovascular-pharmacology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Cardiovascular Pharmacology"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=37006"}],"version-history":[{"count":2,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37006\/revisions"}],"predecessor-version":[{"id":37014,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37006\/revisions\/37014"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=37006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=37006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=37006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}